Page 138 - 202007

blockade of PD-1 and CTLA-4 combined with tumor vac- [58] BAUMEISTER SH，FREEMAN GJ，DRANOFF G，et al.
cine effectively restores T-cell rejection function in tu- Coinhibitory pathways in immunotherapy for cancer[J].
mors-response[J]. Cancer Res，2014，74（2）：633-634. Annu Rev Immunol，2016.DOI：10.1146/annurev-immu-
[50] MOTZER RJ，TANNIR NM，MCDERMOTT DF，et al. nol-032414-112049.
Nivolumab plus ipilimumab versus sunitinib in advanced [59] SALEH R，TOOR SM，KHALAF S，et al. Breast cancer
renal-cell carcinoma[J]. N Engl J Med，2018，378（14）： cells and PD-1/PD-L1 blockade upregulate the expression
1277-1290. of PD-1，CTLA-4，TIM-3 and LAG-3 immune check-
[51] HELLMANN MD，CIULEANU TE，PLUZANSKI A， points in CD4 T cells[J]. Vaccines，2019，7（4）：149-161.
+
et al. Nivolumab plus ipilimumab in lung cancer with a [60] BJOERN J，LYNGAA R，ANDERSEN R，et al. Influence
high tumor mutational burden[J]. N Engl J Med，2018，378 of ipilimumab on expanded tumour derived T cells from
（22）：2093-2104. patients with metastatic melanoma[J]. Oncotarget，2017，8
[52] ZELBA H，BEDKE J，HENNENLOTTER J，et al. PD-1 （16）：27062-27074.
and LAG-3 dominate checkpoint receptor-mediated T-cell [61] CHO H，CHUNG YH. Construction，and in vitro and in vi-
inhibition in renal cell carcinoma[J]. Cancer Immunol vo analyses of tetravalent immunoadhesins[J]. J Microbiol
Res，2019，7（11）：1891-1899. Biotechnol，2012，22（8）：1066-1076.
[53] LICHTENEGGER FS，ROTHE M，SCHNORFEIL FM，et [62] HOLMGAARD RB，ZAMARIN D，MUNN DH，et al. In-
al. Targeting LAG-3 and PD-1 to enhance T cell activa- doleamine 2，3-dioxygenase is a critical resistance mecha-
tion by antigen-presenting cells[J]. Front Immunol，2018. nism in antitumor T cell immunotherapy targeting CTLA-4
DOI：10.3389/fimmu.2018.00385. [J]. J Exp Med，2013，210（7）：1389-1402.
[54] Bristol-myers Squibb. Aninvestigational immuno-therapy [63] HAMID O，GAJEWSKI TF，Frankel AE，et al. Epacado-
study to assess the safety，tolerability and effectiveness of stat plus pembrolizumab in patients with advanced mela-
anti-LAG-3 with and without Anti-PD-1 in the treatment noma：phase 1 and 2 efficacy and safety results from
of solid tumors[EB/OL].[2020-01-18]. https：//clinicaltri- ECHO-202/KEYNOTE-037[J]. Ann Oncol，2017.DOI：10.
als.gov/ct2/show/NCT01968109?cond=NCT01968109& 1093/annonc/mdx377.001.
draw=2&rank=1. [64] FIGUEIREDO M. Keytruda-epacadostatcombo fails pri-
[55] Regeneron Pharmaceutical. Study of REGN3767（Anti- mary goal in phase 3 trial for melanoma，companies an-
LAG-3）with or without REGN2810（Anti-PD1）in ad- nounce[EB/OL].[2020-01-18].https：//immuno-oncology-
vanced cancers[EB/OL].[2020-01-18]. https：//clinicaltri- news.com/2018/04/11/keytruda-epacadostat-fails-primary-
als.gov/ct2/show/NCT03005782?cond=NCT03005782& goal-phase-3-trial-melanoma/.
draw=2&rank=1. [65] Bristol-myers Squibb. An investigational study of Immuno-
[56] LIZOTTE PH，IVANOVA EV，AWAD MM，et al. Multipa- therapy combinations in participants with solid cancers
rametric profiling of non-small-cell lung cancers reveals that are advanced or have spread[EB/OL].[2020-01-18].
distinct immunophenotypes[J]. JCI Insight，2016.DOI： https：//clinicaltrials.gov/ct2/show/NCT03459222.
10.1172/jci.insight.89014. [66] WANG J，SUN J，LIU LN，et al. Siglec-15 as an immune
[57] LIU F，ZENG G，ZHOU S，et al. Blocking Tim-3 or/and suppressor and potential target for normalization cancer
PD-1 reverses dysfunction of tumor-infiltrating lympho- immunotherapy[J]. Nat Med，2019，25（4）：656-666.
cytes in HBV-related hepatocellular carcinoma[J]. Bull （收稿日期：2019-11-14 修回日期：2020-01-19）
Cancer，2018，105（5）：493-501. （编辑：唐晓莲）

《中国药房》杂志——RCCSE中国核心学术期刊，欢迎投稿、订阅

·896 · China Pharmacy 2020 Vol. 31 No. 7 中国药房 2020年第31卷第7期